EU Combo-Product Review In A Rapidly Changing Environment
Croma Pharma executive Arkan Zwick talks about the challenges of getting the drug element of a device-type drug/device combination product reviewed in the EU and how companies should proceed in selecting a notified body to review combinations.
You may also be interested in...
Arkan Zwick Q&A, Part 1: Choosing An EU Notified Body For Drug/Device Combinations In A Rapidly Changing Environment
Selecting a notified body that has capacity, expertise and staying power is a challenge in itself. But when it comes to selecting a good one for drug/device combinations products, how should companies proceed? Croma Pharma executive Arkan Zwick offers his insight in this first part of a two-part Q&A. Check out the second part here.
The UK responsible person is the UK equivalent of the Authorized Representative in the EU. MedTech Europe’s Jesús Rueda gives an update on the early experiences of medtech manufacturers seeking to comply with the UK’s new standalone regulations.
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.